Not available in the U.S.
Peficitinib
SMYRAF
What it isAn oral pan-JAK inhibitor (JAK1, JAK2, JAK3, and TYK2) that blocks cytokine signaling through the JAK-STAT pathway.
Why this oneApproved in Japan (not the US) for rheumatoid arthritis with inadequate response to conventional therapy, including prevention of structural joint damage.
What limits itShares the JAK-inhibitor class risks of serious infections (including herpes zoster reactivation), thromboembolism, and cytopenias.
NO BOXED WARNINGS
Principal riskNo FDA boxed warning.
Classes and tags
Clinical profile
Mechanism of action: Peficitinib ballicule
